NCT06701214 The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository
| NCT ID | NCT06701214 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vanderbilt-Ingram Cancer Center |
| Condition | Clonal Hematopoiesis |
| Study Type | OBSERVATIONAL |
| Enrollment | 800 participants |
| Start Date | 2020-10-28 |
| Primary Completion | 2030-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 800 participants in total. It began in 2020-10-28 with a primary completion date of 2030-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will investigate the association between clonal hematopoiesis and other conditions. Clonal hematopoiesis (CH) refers to the mutations in a person's stem cells which commonly affect people as they get older. These mutations have notably been linked to increased risk of certain cancers as well as increased risk of heart disease.
Eligibility Criteria
Inclusion Criteria: * Patient greater than or equal to 18 years old at time of consent * Able to provide informed consent * Idiopathic cytopenia (ICUS) or idiopathic cytoses (elevated blood counts without disease or explanation); clonal cytopenia of undetermined significance (CCUS), clonal hematopoiesis of indeterminate potential (CHIP) or individuals at higher risk for clonal hematopoiesis (ex. patients with known diagnosis of solid tumors or cardiovascular disease) Exclusion Criteria: * Unable to provide consent * Diagnosis of active hematologic malignancy. For example, a diagnosis of CMML, AML, MDS, MPN; History of hematologic malignancy is NOT exclusionary if in complete remission (e.g. previous myeloma or lymphoma)
Contact & Investigator
Alexander Bick, MD, PhD
PRINCIPAL INVESTIGATOR
Vanderbilt University/Ingram Cancer Center
Frequently Asked Questions
Who can join the NCT06701214 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Clonal Hematopoiesis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06701214 currently recruiting?
Yes, NCT06701214 is actively recruiting participants. Contact the research team at cip@vumc.org for enrollment information.
Where is the NCT06701214 trial being conducted?
This trial is being conducted at Nashville, United States.
Who is sponsoring the NCT06701214 clinical trial?
NCT06701214 is sponsored by Vanderbilt-Ingram Cancer Center. The principal investigator is Alexander Bick, MD, PhD at Vanderbilt University/Ingram Cancer Center. The trial plans to enroll 800 participants.